Multiple Sclerosis (MS) Drugs Market Report

Global and China Multiple Sclerosis (MS) Drugs Industry Market Research Report (2017-2028)

  • POSTDATE：Nov 10, 2022
  • PAGES：176
  • REPORT CODE：GMM1360900
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • This report elaborates on the current development of the Multiple Sclerosis (MS) Drugs industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions along with the strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    Please note that the figures and tables shown in the sample are just for the purpose of demonstration, which may differ from those in the final report.

    Competitive Landscape:

    • Innate Immunotherapeutics

    • Bayer AG

    • Apitope

    • Eli Lilly

    • Genzyme

    • Bayhill Therapeutics

    • Genmab

    • Cinnagen

    • Five Prime Therapeutics

    • Fast Forward Llc

    • Artielle Immunotherapeutics

    • Daiichi Sankyo

    • Antisense Therapeutics

    • Glaxosmithkline

    • Gw Pharmaceuticals

    • Biogen Idec

    Region:

    • China

    • North America

    • Europe

    • APAC

    • Latin America, Middle East and Africa

    Type:

    • Copaxone (Glatiramer Acetate, Copolymer 1)

    • Novantrone (Mitoxantrone)

    • Gilenya (Fingolimod, Fty720)

    • Aubagio (Teriflunomide)

    • Tecfidera (Dimethyl Fumarate)

    • Firategrast (Sb683699, T-0047)

    • Siponimod (Baf312)

    • Others

    Application:

    • RRMS

    • SPMS

    • PPMS

    • PRMS

  • Table of Content

    Chapter 1 Industry Overview & Development Status in Global and China Market

    • 1.1 Multiple Sclerosis (MS) Drugs Industry Overview

      • 1.1.1 Multiple Sclerosis (MS) Drugs Market Scope and Market Segments

      • 1.1.2 Multiple Sclerosis (MS) Drugs Industry Characteristics

      • 1.1.3 Global and China Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

      • 1.1.4 Global and China Multiple Sclerosis (MS) Drugs Production Value and Growth Rate (2017-2028)

    • 1.2 Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate by Type (2017-2028)

      • 1.2.1 Copaxone (Glatiramer Acetate, Copolymer 1)

      • 1.2.2 Novantrone (Mitoxantrone)

      • 1.2.3 Gilenya (Fingolimod, Fty720)

      • 1.2.4 Aubagio (Teriflunomide)

      • 1.2.5 Tecfidera (Dimethyl Fumarate)

      • 1.2.6 Firategrast (Sb683699, T-0047)

      • 1.2.7 Siponimod (Baf312)

      • 1.2.8 Others

    • 1.3 Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate by Application (2017-2028)

      • 1.3.1 RRMS

      • 1.3.2 SPMS

      • 1.3.3 PPMS

      • 1.3.4 PRMS

    • 1.4 Market Analysis by Region

      • 1.4.1 North America Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.2 Europe Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.3 APAC Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

      • 1.4.4 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

    • 1.5 Global Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

      • 1.5.1 Global Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • 1.6 China Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value (2017-2028)

      • 1.6.1 China Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value (2017-2028)

    Chapter 2 Global Multiple Sclerosis (MS) Drugs Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Challenges and Restraints

      • 2.1.2 Opportunities and Potentialities

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape

      • 2.2.1 Market Concentration Rate Analysis

      • 2.2.2 Multiple Sclerosis (MS) Drugs Industry Porter's Five Forces Model Analysis

      • 2.2.3 Multiple Sclerosis (MS) Drugs Industry PEST Analysis

    • 2.3 Multiple Sclerosis (MS) Drugs Industry Chain Analysis

      • 2.3.1 Raw Material Supplies

      • 2.3.2 Multiple Sclerosis (MS) Drugs Downstream Market Analysis

      • 2.3.3 Upstream and Downstream Impacts on Multiple Sclerosis (MS) Drugs Industry

    Chapter 3 Global and China Multiple Sclerosis (MS) Drugs Market, by Manufacturer

    • 3.1 Global and China Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Market Share, by Manufacturer (2021&2022)

      • 3.1.1 Global and China Multiple Sclerosis (MS) Drugs Sales Volume, by Manufacturer (2021&2022)

      • 3.1.2 Global and China Multiple Sclerosis (MS) Drugs Sales Value, by Manufacturer (2021&2022)

      • 3.1.3 Global and China Multiple Sclerosis (MS) Drugs Market Share, by Manufacturer (2021&2022)

    • 3.2 SWOT Analysis on Global and China Multiple Sclerosis (MS) Drugs Market Top 3 Players

    Chapter 4 Global and China Multiple Sclerosis (MS) Drugs Market, by Type (2017-2028)

    • 4.1 Multiple Sclerosis (MS) Drugs Market Trend, by Type

    • 4.2 Global Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales Volume and Market Share, by Type (2017-2028)

      • 4.2.2 Global Multiple Sclerosis (MS) Drugs Sales Value and Market Share, by Type (2017-2028)

      • 4.2.3 Global Multiple Sclerosis (MS) Drugs Price Trend, by Type (2017-2028)

    • 4.3 China Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value, Market Share and Price Trend, by Type

      • 4.3.1 China Multiple Sclerosis (MS) Drugs Sales Volume and Market Share, by Type (2017-2028)

      • 4.3.2 China Multiple Sclerosis (MS) Drugs Sales Value and Market Share, by Type (2017-2028)

      • 4.3.3 China Multiple Sclerosis (MS) Drugs Price Trend, by Type (2017-2028)

    Chapter 5 Global and China Multiple Sclerosis (MS) Drugs Market, by Application (2017-2028)

    • 5.1 Downstream Market Overview

    • 5.2 Global Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Market Share, by Application

      • 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales Volume and Market Share, by Application (2017-2028)

      • 5.2.2 Global Multiple Sclerosis (MS) Drugs Sales Value and Market Share, by Application (2017-2028)

    • 5.3 China Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Market Share, by Application

      • 5.3.1 China Multiple Sclerosis (MS) Drugs Sales Volume and Market Share, by Application (2017-2028)

      • 5.3.2 China Multiple Sclerosis (MS) Drugs Sales Value and Market Share, by Application (2017-2028)

    Chapter 6 Global Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export, by Region (2017-2022)

    • 6.1 China Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • 6.2 North America Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • 6.3 Europe Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • 6.4 APAC Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • 6.5 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    Chapter 7 North America Multiple Sclerosis (MS) Drugs Market Analysis

    • 7.1 North America Multiple Sclerosis (MS) Drugs Market, by Type

    • 7.2 North America Multiple Sclerosis (MS) Drugs Market, by Application

    • 7.3 North America Multiple Sclerosis (MS) Drugs Market Analysis and Forecast, by Country

      • 7.3.1 United States Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.2 Canada Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 7.3.3 Mexico Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 8 Europe Multiple Sclerosis (MS) Drugs Market Analysis

    • 8.1 Europe Multiple Sclerosis (MS) Drugs Market, by Type

    • 8.2 Europe Multiple Sclerosis (MS) Drugs Market, by Application

    • 8.3 Europe Multiple Sclerosis (MS) Drugs Market Analysis and Forecast, by Country

      • 8.3.1 Germany Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.2 UK Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.3 France Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.4 Italy Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.5 Nordic Countries Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.6 Spain Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.7 Belgium Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.8 Poland Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.9 Russia Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 8.3.10 Turkey Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 9 APAC Multiple Sclerosis (MS) Drugs Market Analysis

    • 9.1 APAC Multiple Sclerosis (MS) Drugs Market, by Type

    • 9.2 APAC Multiple Sclerosis (MS) Drugs Market, by Application

    • 9.3 APAC Multiple Sclerosis (MS) Drugs Market Analysis and Forecast, by Country

      • 9.3.1 China Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.2 Japan Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.3 Australia and New Zealand Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.4 India Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.5 ASEAN Countries Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 9.3.6 South Korea Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 10 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Market Analysis

    • 10.1 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Market, by Type

    • 10.2 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Market, by Application

    • 10.3 Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Market Analysis and Forecast, by Country

      • 10.3.1 GCC Countries Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.2 Brazil Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.3 Nigeria Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.4 South Africa Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

      • 10.3.5 Argentina Multiple Sclerosis (MS) Drugs Sales Volume, Sales Value and Growth Rate (2017-2028)

    Chapter 11 Global and China Multiple Sclerosis (MS) Drugs Company Profiles

      • 11.1 Innate Immunotherapeutics

        • 11.1.1 Innate Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.1.2 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.1.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.2 Bayer AG

        • 11.2.1 Bayer AG Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.2.2 Bayer AG Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.3 Apitope

        • 11.3.1 Apitope Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.3.2 Apitope Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.3.3 Apitope Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.4 Eli Lilly

        • 11.4.1 Eli Lilly Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.4.2 Eli Lilly Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.4.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.5 Genzyme

        • 11.5.1 Genzyme Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.5.2 Genzyme Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.5.3 Genzyme Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.6 Bayhill Therapeutics

        • 11.6.1 Bayhill Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.6.2 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.6.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.7 Genmab

        • 11.7.1 Genmab Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.7.2 Genmab Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.8 Cinnagen

        • 11.8.1 Cinnagen Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.8.2 Cinnagen Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.8.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.9 Five Prime Therapeutics

        • 11.9.1 Five Prime Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.9.2 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.9.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.10 Fast Forward Llc

        • 11.10.1 Fast Forward Llc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.10.2 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.10.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.11 Artielle Immunotherapeutics

        • 11.11.1 Artielle Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.11.2 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.11.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.12 Daiichi Sankyo

        • 11.12.1 Daiichi Sankyo Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.12.2 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.12.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.13 Antisense Therapeutics

        • 11.13.1 Antisense Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.13.2 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.13.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.14 Glaxosmithkline

        • 11.14.1 Glaxosmithkline Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.14.2 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.14.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.15 Gw Pharmaceuticals

        • 11.15.1 Gw Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.15.2 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.15.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

      • 11.16 Biogen Idec

        • 11.16.1 Biogen Idec Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

        • 11.16.2 Biogen Idec Multiple Sclerosis (MS) Drugs Product Profiles, Application and Specification

        • 11.16.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    Chapter 12 Multiple Sclerosis (MS) Drugs Industry Investment Prospect and Risk Assessment

    • 12.1 Multiple Sclerosis (MS) Drugs Industry Investment Prospect Assessment

      • 12.1.1 Investment Opportunities in Segmented Markets

      • 12.1.2 Investment Opportunities in Regional Markets

      • 12.1.3 Investment Opportunities in Subdivided Industries

    • 12.2 Multiple Sclerosis (MS) Drugs Industry Investment Risk Assessment

      • 12.2.1 Competitive Risk Analysis

      • 12.2.2 Technology Risk Analysis

      • 12.2.3 Policies and Enterprise System Risk Analysis

    List of Tables and Figures

    • Figure Global Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Production Value and Growth Rate (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Production Value and Growth Rate (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Copaxone (Glatiramer Acetate, Copolymer 1) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Novantrone (Mitoxantrone) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Gilenya (Fingolimod, Fty720) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Aubagio (Teriflunomide) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Tecfidera (Dimethyl Fumarate) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Firategrast (Sb683699, T-0047) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Siponimod (Baf312) (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of Others (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of RRMS (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of SPMS (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of PPMS (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Market Size and Growth Rate of PRMS (2017-2028)

    • Figure North America Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

    • Figure Europe Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

    • Figure APAC Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

    • Figure Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Consumption Market Size and Growth Rate (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value, Gross and Gross Margin (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Volume, Price, Sales Value (2017-2028)

    • Figure Porter's Five Forces Model Analysis

    • Figure Industry PEST Analysis

    • Table Global and China Multiple Sclerosis (MS) Drugs Sales Volume, by Manufacturer (2021&2022)

    • Table Global and China Multiple Sclerosis (MS) Drugs Sales Value, by Manufacturer (2021&2022)

    • Table Global and China Multiple Sclerosis (MS) Drugs Market Share, by Manufacturer (2021&2022)

    • Figure Global and China Multiple Sclerosis (MS) Drugs Market Share, by Manufacturer in 2021

    • Figure Global and China Multiple Sclerosis (MS) Drugs Market Share, by Manufacturer in 2022

    • Table Global Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Value, by Type (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Value Share, by Type (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Price Trend, by Type (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Value, by Type (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Value Share, by Type (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Price Trend, by Type (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Value, by Application (2017-2028)

    • Table Global Multiple Sclerosis (MS) Drugs Sales Value Share, by Application (2017-2028)

    • Figure Global Multiple Sclerosis (MS) Drugs Sales Value Share, by Application (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Value, by Application (2017-2028)

    • Table China Multiple Sclerosis (MS) Drugs Sales Value Share, by Application (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Value Share, by Application (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • Figure North America Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • Figure Europe Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • Figure APAC Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • Figure Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Production, Import, Consumption and Export (2017-2022)

    • Table North America Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table North America Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure North America Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table North America Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table North America Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure North America Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure United States Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure United States Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Canada Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Canada Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Mexico Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Mexico Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Table Europe Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table Europe Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure Europe Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table Europe Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table Europe Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure Europe Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure Germany Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Germany Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure UK Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure UK Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure France Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure France Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Italy Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Italy Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Nordic Countries Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Nordic Countries Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Spain Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Spain Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Belgium Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Belgium Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Poland Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Poland Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Russia Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Russia Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Turkey Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Turkey Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Table APAC Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table APAC Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure APAC Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table APAC Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table APAC Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure APAC Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure China Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Japan Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Japan Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Australia and New Zealand Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure India Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure India Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure ASEAN Countries Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure ASEAN Countries Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure South Korea Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure South Korea Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Table Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Figure Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume Share, by Type (2017-2028)

    • Table Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume, by Application (2017-2028)

    • Table Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure Latin America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Volume Share, by Application (2017-2028)

    • Figure GCC Countries Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure GCC Countries Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Brazil Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Brazil Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Nigeria Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Nigeria Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure South Africa Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure South Africa Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Figure Argentina Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate (2017-2028)

    • Figure Argentina Multiple Sclerosis (MS) Drugs Sales Value and Growth Rate (2017-2028)

    • Table Innate Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Innate Immunotherapeutics Product Profiles, Application and Specification

    • Table Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Bayer AG Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Bayer AG Product Profiles, Application and Specification

    • Table Bayer AG Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Apitope Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Apitope Product Profiles, Application and Specification

    • Table Apitope Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Eli Lilly Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Eli Lilly Product Profiles, Application and Specification

    • Table Eli Lilly Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Genzyme Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Genzyme Product Profiles, Application and Specification

    • Table Genzyme Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Bayhill Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Bayhill Therapeutics Product Profiles, Application and Specification

    • Table Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Genmab Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Genmab Product Profiles, Application and Specification

    • Table Genmab Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Cinnagen Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Cinnagen Product Profiles, Application and Specification

    • Table Cinnagen Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Five Prime Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Five Prime Therapeutics Product Profiles, Application and Specification

    • Table Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Fast Forward Llc Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Fast Forward Llc Product Profiles, Application and Specification

    • Table Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Artielle Immunotherapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Artielle Immunotherapeutics Product Profiles, Application and Specification

    • Table Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Daiichi Sankyo Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Daiichi Sankyo Product Profiles, Application and Specification

    • Table Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Antisense Therapeutics Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Antisense Therapeutics Product Profiles, Application and Specification

    • Table Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Glaxosmithkline Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Glaxosmithkline Product Profiles, Application and Specification

    • Table Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Gw Pharmaceuticals Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Gw Pharmaceuticals Product Profiles, Application and Specification

    • Table Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

    • Table Biogen Idec Basic Information, Plants Distribution, Sales Region, Competitors and Market Position

    • Table Biogen Idec Product Profiles, Application and Specification

    • Table Biogen Idec Multiple Sclerosis (MS) Drugs Sales Volume, Revenue, Price, Gross and Gross Margin (2017-2022)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US